US Retail Drug Spending Growth Accelerates In 2019, Driven Mostly By Utilization, Not Prices
Price growth for brands slowed in 2019 and rebates increased at the lowest rate since 2012, the latest CMS National Health Expenditures Report finds.
You may also be interested in...
Plan includes new 30% manufacturer discount in the US Medicare Part D catastrophic phase, which manufacturers will oppose as too high. But it also caps beneficiary cost sharing, a long-sought industry goal.
Medicare may look to bolster evidence on Biogen’s potential Alzheimer’s treatment, if approved, with a national coverage decision requiring the collection of clinical data in the postmarket setting.
Products from Bristol-Myers Squibb, Gilead and J&J might be eligible for supplemental reimbursement under hospital payment proposed rule that could help promote uptake.